Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2012 | review article | Ausgabe 23-24/2012

Wiener klinische Wochenschrift 23-24/2012

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 23-24/2012
Autoren:
MD Peter Valent, Michel Arock, Patrizia Bonadonna, Knut Brockow, Sigurd Broesby-Olsen, Luis Escribano, Karoline V. Gleixner, Clive Grattan, Emir Hadzijusufovic, Hans Hägglund, Olivier Hermine, Hans-Peter Horny, Hanneke C. Kluin-Nelemans, Marcus Maurer, Marek Niedoszytko, Boguslaw Nedoszytko, Gunnar Nilsson, Hanneke N. G. Oude-Elberink, Alberto Orfao, Deepti Radia, Andreas Reiter, Frank Siebenhaar, Karl Sotlar, Wolfgang R. Sperr, Massimo Triggiani, Jaap J. VanDoormaal, Judit Várkonyi, Selim Yavuz, Karin Hartmann

Summary

The European Competence Network on Mastocytosis (ECNM) was initiated in 2002 as a multidisciplinary and multinational cooperative approach to increase awareness and to improve diagnosis and therapy of mastocytosis. The network is composed of local centers, physicians, and scientists who have dedicated their work to patients with mastocytosis. A strategic goal of the ECNM is to provide the best available information about the disease to patients and physicians. During the past 10 years, the ECNM has expanded to various countries and contributed successfully to the development of markers, definitions, and standards in the field of mastocytosis. Members of the ECNM organized Annual Meetings in Europe and two Working Conferences on Mastocytosis in Vienna (in 2005 and 2010), and initiated and supported several preclinical and clinical trials. In all these activities, representatives of the ECNM cooperate closely with their US colleagues, with patient-organizations in Europe and in the USA, and with other scientific networks. The ECNM also launched a mastocytosis registry that has been activated in 2012. Using the central database of this registry, cooperative multicenter studies, which should include sufficient numbers of patients and robust evaluations, will be conducted. These studies will increase our knowledge about optimal management and therapy of patients with mastocytosis in the future.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 23-24/2012

Wiener klinische Wochenschrift 23-24/2012 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

175 Jahre Gesellschaft der Ärzte in Wien